Cytokinetics Ownership | Who Owns Cytokinetics?

Overview Forecast RevenueFinancials Chart Transcripts

Cytokinetics Ownership Summary

Cytokinetics is owned by 13.64% institutional investors, 0.77% insiders, and 85.60% retail investors. Blackrock is the largest institutional shareholder, holding 14.40% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.41% of its assets in Cytokinetics shares.

CYTK Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Cytokinetics	13.64%	0.77%	85.60%
Sector	Healthcare Stocks	279.42%	10.64%	-190.05%
Industry	Biotech Stocks	64.05%	10.69%	25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	14.67M	14.40%	$794.97M
Blackrock funding, inc. /de	15.47M	13.14%	$727.68M
Vanguard group	11.92M	10.13%	$560.52M
Fmr	10.79M	9.17%	$507.78M
T. rowe price investment management	10.75M	9.14%	$505.78M
Wellington management group llp	7.89M	6.70%	$371.08M
State street	6.17M	5.24%	$290.11M
Deep track capital, lp	3.07M	2.59%	$123.54M
Geode capital management	2.84M	2.41%	$133.69M
Rtw investments, lp	2.72M	2.30%	$109.36M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rp management	980.39K	22.73%	$51.76M
Sarissa capital management lp	833.80K	12.15%	$39.22M
Great point partners	370.00K	7.88%	$14.87M
Vestal point capital, lp	2.59M	7.43%	$104.11M
Boxer capital	2.10M	5.99%	$113.78M
Superstring capital management lp	129.39K	5.27%	$6.09M
Melqart asset management (uk)	999.45K	5.24%	$40.17M
Dafna capital management	398.10K	4.54%	$16.00M
Allostery investments lp	70.00K	4.06%	$2.81M
Integral health asset management	1.00M	4.01%	$47.04M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	14.67M	0.02%	2.26M
Capital investors	1.10M	0.01%	1.10M
T. rowe price investment management	10.75M	0.31%	1.06M
Norges bank	989.72K	0.01%	989.72K
Ubs group	1.20M	0.01%	888.44K

Top Sellers

Holder	Shares	% Assets	Change
Darwin global management	-	-	-4.58M
Pfm health sciences, lp	-	-	-1.76M
Fmr	10.79M	0.03%	-1.30M
Logos global management lp	-	-	-900.00K
Pentwater capital management lp	220.00K	0.07%	-870.00K

New Positions

Holder	Shares	% Assets	Change	Value
Capital investors	1.10M	0.01%	1.10M	$51.56M
Norges bank	989.72K	0.01%	989.72K	$46.56M
Paradigm biocapital advisors lp	858.66K	1.58%	858.66K	$34.51M
Groupama asset managment	350.00K	0.01%	350.00K	$421.29K
Cutter capital management, lp	175.00K	3.06%	175.00K	$7.03M

Sold Out

Holder	Change
True wealth design	-1.00
New england capital financial advisors	-1.00
Financial gravity asset management	-2.00
Financial management professionals	-5.00
American capital advisory	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	25	-93.40%	16,158,180	-87.73%	13	0.11%	15	-91.28%	5	-96.09%
Dec 31, 2024	374	-5.32%	131,318,059	-2.91%	111	0.84%	166	-12.17%	128	29.29%
Sep 30, 2024	390	0.52%	135,010,879	-0.29%	114	0.65%	187	-6.50%	99	-2.94%
Jun 30, 2024	388	-14.35%	135,400,422	16.07%	132	1.01%	200	-11.11%	102	-22.14%
Mar 31, 2024	453	6.34%	116,652,886	2.18%	114	0.82%	225	10.29%	131	11.02%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	4.07M	3.41%	-
iShares Core S&P Mid-Cap ETF	3.90M	3.26%	254.00
Vanguard Total Stock Mkt Idx Inv	3.80M	3.18%	16.51K
Vanguard US Total Market Shares ETF	3.75M	3.15%	128.42K
Vanguard Small Cap Index	2.92M	2.44%	-58.37K
iShares Russell 2000 ETF	2.80M	2.34%	-45.23K
T. Rowe Price Capital Appreciation	2.44M	2.04%	41.02K
T. Rowe Price Mid-Cap Growth	2.25M	1.88%	268.00K
T. Rowe Price US Mid-Cap Growth Equity	2.25M	1.88%	267.30K
T. Rowe Price Small-Cap Value	2.10M	1.76%	288.91K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 05, 2025	Malik Fady Ibraham	EVP Research & Development	Sell	$72.68K
Jul 29, 2025	Blum Robert I	President & CEO	Sell	$182.25K
Jul 22, 2025	Malik Fady Ibraham	EVP Research & Development	Sell	$74.94K
Jul 14, 2025	Blum Robert I	President & CEO	Sell	$190.75K
Jul 08, 2025	Malik Fady Ibraham	EVP Research & Development	Sell	$67.52K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	6
2025 Q2	-	19
2025 Q1	-	22
2024 Q4	-	20
2024 Q3	-	25

CYTK Ownership FAQ

Who Owns Cytokinetics?

Cytokinetics shareholders are primarily institutional investors at 13.64%, followed by 0.77% insiders and 85.59% retail investors. The average institutional ownership in Cytokinetics's industry, Biotech Stocks , is 64.05%, which Cytokinetics falls below.

Who owns the most shares of Cytokinetics?

Cytokinetics’s largest shareholders are Blackrock (14.67M shares, 14.40%), Blackrock funding, inc. /de (15.47M shares, 13.14%), and Vanguard group (11.92M shares, 10.13%). Together, they hold 37.67% of Cytokinetics’s total shares outstanding.

Does Blackrock own Cytokinetics?

Yes, BlackRock owns 14.40% of Cytokinetics, totaling 14.67M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 794.97M$. In the last quarter, BlackRock increased its holdings by 2.26M shares, a 18.19% change.

Who is Cytokinetics’s biggest shareholder by percentage of total assets invested?

Rp management is Cytokinetics’s biggest shareholder by percentage of total assets invested, with 22.73% of its assets in 980.39K Cytokinetics shares, valued at 51.76M$.

Who is the top mutual fund holder of Cytokinetics shares?

Vanguard Health Care Inv is the top mutual fund holder of Cytokinetics shares, with 3.41% of its total shares outstanding invested in 4.07M Cytokinetics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools